LT 3001

Drug Profile

LT 3001

Alternative Names: LT3001

Latest Information Update: 02 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lumosa Therapeutics
  • Class Antithrombotics; Neuroprotectants; Peptides; Small molecules
  • Mechanism of Action Antioxidants; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Stroke

Most Recent Events

  • 28 Jul 2017 Phase-I clinical trials in Stroke (In volunteers) in USA (unspecified route)
  • 22 Jun 2017 Lumosa Therapeutics approves IND application for LT-3001 in Stroke
  • 22 Jun 2017 Lumosa Therapeutics files an IND application with the US FDA in USA for Stroke prior to June 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top